1. FDA Moves Toward Identifying Medical Devices Using LLMs and Foundation Models
Published: September 4, 2026
The FDA updated its Artificial Intelligence-Enabled Medical Devices information.
One of the most notable additions is the agency's statement that it intends to explore methods for identifying and tagging medical devices that incorporate foundation models, including large language models (LLMs) and multimodal AI architectures.
The FDA also encourages sponsors to include appropriate information about AI functionality in publicly available submission summaries to make such devices easier to identify in future updates.
As generative AI becomes increasingly integrated into SaMD and other medical devices, regulatory transparency may evolve from simply indicating that a device uses AI to clarifying what type of model is used and for which clinical function.
Official source: FDA — Artificial Intelligence-Enabled Medical Devices
2. FDA Adds New FAQ on PFAS Used in Medical Devices
Published: September 1, 2026
The FDA updated its information on PFAS in medical devices and added a new FAQ section.
The agency emphasized that large-molecule fluoropolymers such as PTFE used in medical devices differ from lower-molecular-weight PFAS associated with environmental contamination and health concerns.
Fluoropolymers are widely used in catheters, cardiovascular implants, tubing, wound dressings, and other devices because of their biocompatibility, durability, electrical resistance, and lubricity.
Based on currently available scientific evidence, the FDA says it is not aware of evidence demonstrating adverse public-health effects from fluoropolymers used in medical devices and sees no reason at present to restrict their continued use.
This is particularly relevant as manufacturers evaluate material strategies and supply-chain risks amid growing global attention to PFAS regulation.
Official source: FDA — PFAS in Medical Devices: What You Need to Know
3. Medtronic Invests Approximately $700 Million in Cornerstone Robotics
Published: September 1, 2026
Medtronic announced a strategic partnership with surgical robotics company Cornerstone Robotics involving an investment of approximately $700 million.
The agreement gives Medtronic rights to distribute Cornerstone's Sentire surgical robotic system in selected markets outside the United States where the platform has regulatory approval.
Medtronic plans to market Sentire alongside its own Hugo robotic-assisted surgery platform, allowing the company to address different clinical settings, procedures, and economic models.
With global adoption of robotic-assisted surgery still in the single digits, the agreement represents a strategy based on offering multiple robotic platforms rather than relying on a single system.
The move is also significant in the context of competition with Intuitive Surgical, which remains the dominant player in surgical robotics.
Official source: Medtronic — Strategic Partnership with Cornerstone Robotics
4. Medtronic Invests Up to $80 Million in Pi-Cardia for Complex TAVR
Published: September 1, 2026
Medtronic announced a strategic investment of up to $80 million in Pi-Cardia.
Pi-Cardia's ShortCut device is a leaflet-modification technology designed to reduce the risk of coronary obstruction during procedures such as valve-in-valve TAVR.
Medtronic is expected to become the exclusive global commercial distributor of ShortCut in 2027, with planned expansion across the United States, Europe, Japan, and other international markets.
The agreement also provides Medtronic with an option to acquire Pi-Cardia after predefined milestones are achieved, with an estimated upfront acquisition price of up to $210 million.
As TAVR patients live longer and repeat procedures become more common, investment is expanding beyond replacement valves themselves toward adjunct technologies that enable future coronary access and reintervention.
Official source: Medtronic — Strategic Investment in Pi-Cardia
5. Philips Introduces New eV14-2v Transvaginal Ultrasound Transducer
Published: September 3, 2026
Philips introduced the new eV14-2v transvaginal transducer for obstetric and gynecologic ultrasound.
The device has received FDA 510(k) clearance and CE marking and is designed to support a broad range of gynecologic and early-obstetric examinations with a single probe.
According to Philips, the new transducer provides 41.7% greater penetration, 10% better 2D resolution, and a 22% reduction in weight compared with its predecessor.
The product illustrates how ultrasound manufacturers are increasingly competing not only on image quality, but also on workflow efficiency, ergonomics, and patient experience.
Official source: Philips — eV14-2v Transvaginal Transducer
6. Precision IO Adds AI Liver-Tumor Segmentation and Robotic Needle Guidance to Epione
Published: September 3, 2026
Precision IO Group announced new capabilities for its Epione robotic platform for percutaneous tumor ablation.
The new Smart Seg AI software uses deep-learning algorithms trained on thousands of CT images to assist with liver-tumor segmentation.
Integration with GE HealthCare's Allia Moveo INTERACT Touch platform brings 3D imaging, treatment planning, and robotic needle guidance into a more unified workflow.
Epione is CE marked in Europe for abdominal, chest, and musculoskeletal indications and FDA cleared in the United States for CT-guided abdominal ablation.
The progression from AI image analysis to treatment planning and robotic intervention demonstrates how interventional oncology platforms are evolving toward integrated procedural ecosystems.
Primary source: Precision IO Group — Epione Robotic Platform Features at CIRSE 2026
7. Japan Announces September 1 Reimbursement Listings for EUS, Biliary Stents, TAVR and iPSC Therapy
Notification: August 31, 2026 / Effective: September 1, 2026
Japan's Ministry of Health, Labour and Welfare announced new medical-device reimbursement listings effective September 1.
Under the A2 category, Fujifilm's EG-840UP and EG-840UT endoscopic ultrasound systems were among the newly listed products.
New C1 listings included:
- Terumo Dual View: JPY 132,000
- SB-Kawasumi Antler biliary stent: JPY 340,000 / JPY 345,000
- Edwards Lifesciences SAPIEN 3 Ultra RESILIA: JPY 4,940,000
Under the C2 category, Cuorips' ReHeart was listed as a human iPSC-derived cardiomyocyte sheet at JPY 53,200,000.
The notification is notable for its breadth, covering gastrointestinal endoscopy, biliary intervention, structural heart therapy, and regenerative medicine.
For companies entering Japan, the listings also demonstrate the importance of considering reimbursement classification and pricing strategy alongside regulatory approval.
Official source: Ministry of Health, Labour and Welfare, Japan — Medical Device Reimbursement Notice, August 31, 2026
8. Stryker Japan Launches ProCinch and Enters ACL Reconstruction Market
Published: September 1, 2026
Stryker Japan announced the launch of ProCinch, a fixation device for knee-ligament reconstruction, beginning in September.
The device is used to secure grafts during procedures such as anterior cruciate ligament reconstruction, marking Stryker's full-scale entry into the ACL reconstruction market in Japan.
Stryker already offers arthroscopy systems, meniscal repair products, and artificial ligaments, and the launch further expands its sports-medicine portfolio.
The move reflects a broader strategy to provide solutions across the full spectrum of knee treatment, including younger and sports-injury patients in addition to joint-replacement patients.
Official source: Stryker Japan — Launch of ProCinch
9. Stryker to Acquire ZuriMED and Expand Shoulder and Sports Medicine Portfolio
Published: August 31, 2026
Stryker signed a definitive agreement to acquire ZuriMED, a Swiss medical-device company.
ZuriMED developed the FiberLocker System, a soft-tissue augmentation technology designed to reinforce rotator-cuff repair and increase biomechanical strength.
Rotator-cuff retear remains an important clinical challenge, and FiberLocker is intended to address this failure mode by strengthening the repair construct.
Announced in the same week as Stryker Japan's ProCinch launch, the transaction highlights Stryker's continued investment in sports medicine and shoulder surgery as growth areas.
Financial terms were not disclosed.
Official source: Stryker — Definitive Agreement to Acquire ZuriMED
Summary
This week offered a clear view of several emerging competitive themes in the medical-device industry.
The FDA is moving toward greater transparency for AI-enabled medical devices, including products that incorporate LLMs and foundation models.
Medtronic, meanwhile, committed up to approximately $780 million across surgical robotics and TAVR-adjacent technologies, while Precision IO demonstrated how AI, medical imaging, and robotics are increasingly being integrated into a single procedural workflow.
In Japan, the September reimbursement update covered EUS, biliary stents, TAVR, and an iPSC-derived cardiomyocyte sheet, making this an important week not only for regulatory affairs but also for market access and reimbursement strategy.
October 17, 2026 update: Added links to the official announcements and notice cited in the article. The reporting period and original publication date are unchanged.